Purple Biotech Debuts Scientific Advisory Board
25 avr. 2023 08h00 HE
|
Purple Biotech Ltd.
Scientific Advisory Board inaugurates new KOL support structure for Purple Biotech Three advisors bring expertise as researchers, oncologists and academicians REHOVOT, Israel, April 25, 2023 (GLOBE...
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
19 avr. 2023 08h15 HE
|
Purple Biotech Ltd.
New preclinical data from study presented at the American Association for Cancer Research 2023 Annual Meeting, 18 April 2023 REHOVOT, Israel, April 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech...
Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
18 avr. 2023 07h00 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, April 18, 2023 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class,...
Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
24 mars 2023 07h00 HE
|
Purple Biotech Ltd.
Board of Directors appoints Isaac Israel, Board member and former CEO, as acting CEOCompany’s business plan and clinical development programs continue as planned REHOVOT, Israel, March 24, 2023 ...
Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
16 mars 2023 07h00 HE
|
Purple Biotech Ltd.
Reduction in neutrophil extracellular traps (NETs) markersPotential association between patient survival and CEACAM1 positive lymphocytes REHOVOT, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- ...
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
14 févr. 2023 07h01 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results
08 févr. 2023 07h12 HE
|
Purple Biotech Ltd.
Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Purple Biotech...
Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer
02 févr. 2023 07h00 HE
|
Purple Biotech Ltd.
Immunorizon’s lead compound targets 5T4 antigen and conditionally activates T cells and natural killer (NK) cells Conditional activation of T cells is designed to provide a wide therapeutic...
Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments
03 janv. 2023 07h00 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis
15 nov. 2022 07h00 HE
|
Purple Biotech Ltd.
Data demonstrate suppression by CM24 of NET-promoting cancer cell migration and metastasis Findings suggest potential new treatment target for metastasis REHOVOT, Israel, Nov. 15, 2022 ...